Eleven obsessive-compulsive patients underwent a prospective open-label
trial of fluoxetine monotherapy followed by buspirone augmentation. The
combination therapy was statistically superior to fluoxetine monotherapy.
The results point to the importance of the 5-HT1a receptor in
obsessive-compulsive disorder.
Abstract Teaser